HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies

Executive Summary

Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.

You may also be interested in...



No Hiding In Social Media: More False COVID-19 Treatment Claims Found By US Agencies

FDA and FTC's latest warning letters include the first firm marketing CBD products linked with bogus COVID-19 claims. Latest warnings also mark the first the agencies submitted based completely or nearly entirely on regulatory violations found in businesses social media postings.

US FDA Suspends Domestic Inspections As Staff Work Remotely In Covid-19 Response

Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the virus, and breakthrough products such as cancer treatments.

House Leaders Suggest FTC Crack Down On Pandemic-Spurred Price Gouging, Hoarding

The same day Judiciary Chairman Jerrold Nadler and Energy and Commerce Chairman Frank Pallone submit a letter to the FTC, the agency announced work and travel schedule changes it is making in response to the Covid-19 pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel